Following the delivery of its first cohort and strong demand for Cohort 2, Medilink Midlands is now welcoming applications for Cohort 3 of its venture readiness programme, the Medilink Midlands Innovation Builder (MMIB), launching in early 2026.
MMIB has quickly become a valued route for health and medtech innovators to scale faster and smarter. The programme provides tailored support to help founders refine commercial strategies, prepare for investment, and connect with influential partners across the healthcare innovation ecosystem.
Launched in Spring 2025, the first MMIB cohort brought together five pioneering companies from the UK, USA, and Europe, developing breakthrough technologies in diagnostics, AI, wearables, and rehabilitation:
-
Acies Medical – combining nanotech, AI, pressure and light sensors to verify needle tip placement with precision.
-
Neuro20 Technologies Corp – delivering full-body wearable electrical stimulation to support therapy through improved muscle activation, circulation, and mobility.
-
Peak Medtek Ltd – have developed a personalised solution aimed at reducing nighttime falls in our vulnerable populations.
-
PROSTPERIA – an AI-powered tool enhancing prostate cancer screening accuracy while reducing unnecessary biopsies.
-
XRnostics Limited – enabling CT, MRI and ultrasound data to be viewed in immersive virtual reality for clinical planning and device testing.
Each company received expert guidance on business model validation, clinical and regulatory strategy, and investment readiness, alongside 1:1 mentoring, market insight, and access to Medilink Midlands’ extensive sector network.
Christian Kumar, Medilink Midlands’ Entrepreneur in Residence, said:
“MMIB is more than a programme – it’s due diligence in action. Our goal is to ensure every graduate is investor-ready and strategically positioned for growth.”
In June, the inaugural cohort showcased their ventures at MMIB Venture Day, hosted by Medilink Midlands Patron Mills & Reeve in Birmingham. Founders pitched to a focused audience of investors, commercial leaders, and healthcare stakeholders, gaining valuable feedback and opening new opportunities. Investors included Minerva Business Angels, Future Planet Capital, Mercia, and the British Business Bank.
Building on this platform, three MMIB ventures, Acies Medical, Neuro20 Technologies Corp, and PROSTPERIA, went on to present at the Med-Tech Innovation Conference and Expo, where Medilink Midlands was headline sponsor.
Dr Thomas J Adler, Co-Founder and CEO of Peak Medtek Ltd, said:
“Venture Day was an excellent way to build context around the significant added value of the MMIB programme. It was a pleasure to support the pilot year and connect with esteemed colleagues.”
To better align with the evolving needs of ventures, MMIB has evolved into a new two-tiered structure: Accelerate and Elevate.
-
Accelerate – supporting early-stage companies with strong foundations, an investment readiness health check, and exposure via a dedicated HIVE event.
-
Elevate – building on Accelerate with bespoke, venture-specific support and an exclusive Investor HIVE event for targeted introductions.
MMIB also draws on the talent and expertise of the Medilink Midlands member network, with specialists across IP, regulation, and clinical validation contributing to programme delivery.
David Hawkins, CTO, Co-Founder and Principal Consultant at Sotas Ltd, commented:
“Medilink Midlands has a wealth of expertise and talent within its community, and we’re proud to bring these great minds together to help innovation thrive.”
With applications for Cohort 2 currently being triaged, Cohort 3 is now open for early 2026.
How to Apply:
Visit MMIB here or register interest: [email protected]
Programme fees
-
Accelerate – £1,000
Includes an investment readiness health check and access to the Medilink Midlands network through a dedicated HIVE event. -
Elevate – £2,000
Includes everything in Accelerate, plus bespoke one-to-one support and access to an exclusive Investor HIVE event.
Each application is assessed to ensure ventures are placed in the tier where they will gain the most meaningful impact. The support provided is valued at more than £15,000, representing a highly subsidised opportunity to accelerate growth.